Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Mayne Pharma Group ( (AU:MYX) ).
Mayne Pharma Group Limited recently experienced a notable drop in its share price, which prompted a query from the ASX. The company clarified that it is not aware of any undisclosed information that could explain the trading activity. However, it acknowledged the public release of an ‘untitled letter’ from the FDA regarding promotional claims for its product NEXTSTELLIS®, which may have led to market speculation. Mayne Pharma is preparing a response to the FDA and plans to address market concerns through a further announcement.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is a pharmaceutical company that focuses on developing and manufacturing branded and generic pharmaceutical products. The company operates in the healthcare industry, providing a range of therapeutic products to address various medical needs.
Average Trading Volume: 797,278
Technical Sentiment Signal: Hold
Current Market Cap: A$560.6M
For a thorough assessment of MYX stock, go to TipRanks’ Stock Analysis page.